BioSpace News Archive

Business

ImmunoGen and Gilead Team Up to Target AML

ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML.

December 9, 2022
·
2 min read
·
Lisa Munger
Drug Development

With Two Wins at SABCS, AstraZeneca Continues Breast Cancer Rally

AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.

December 9, 2022
·
2 min read
·
Tristan Manalac
Drug Development

UCB Reports Positive Pivotal for New Approach to Hidradenitis Suppurativa (Updated)

UCB shared positive top-line results Friday from two Phase III studies of bimekizumab for adults with moderate to severe hidradenitis suppurativa.

December 9, 2022
·
2 min read
·
Kate Goodwin
Drug Development

Autolus Meets Phase II Acute Lymphoblastic Leukemia Endpoint

Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.

December 9, 2022
·
3 min read
·
Alex Keown
Drug Development

FDA Action Alert: Mirati, Coherus/Shanghai Junshi, Gilead and More

As 2022 comes to its conclusion, the FDA has a handful of Prescription Drug User Fee Amendments still to wrap up. Here’s a look at that and more.

December 9, 2022
·
2 min read
·
Mark Terry
Business

Exelixis/Roche Combo Fails to Improve Overall Survival in NSCLC

A combination of Exelixis’ cabozantinib and Roche’s Tecentriq missed the primary endpoint of overall survival in a Phase III study.

December 9, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Setting the Stage for ASH 2022

At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs.

December 9, 2022
·
6 min read
·
Rosemary Scott and Heather McKenzie
Policy

Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at December 1, 2022:.

December 9, 2022
·
4 min read
Business

Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursday, December 15, 2022.

December 9, 2022
·
2 min read
The 1st Boao International Conference on Real World Studies of Medical Products Held in Hainan

On December 8 , the first Boao International Conference on Real World Studies of Medical Products was held in Hainan Province, with the theme of “Real World Data Studies and Innovative Development and Supervision of Medical Products”.

December 9, 2022
·
2 min read